Ginsenoside Rk2
- CAS NO.：364779-14-6
- Empirical Formula: C36H60O7
- Molecular Weight: 604.86
- MDL number: MFCD11656143
- Update Date: 2026-04-24 14:59:12
What is Ginsenoside Rk2?
The Uses of Ginsenoside Rk2
Ginsenoside RK2 exhibits in vitro cytotoxicity against five human cancer cell lines. Also, it exhibits inhibitory effect on LPS-induced IL-12 production.
Properties of Ginsenoside Rk2
| Boiling point: | 693.9±55.0 °C(Predicted) |
| Density | 1.17±0.1 g/cm3(Predicted) |
| storage temp. | Amber Vial, Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 12.91±0.70(Predicted) |
| color | White to Off-White |
| Stability: | Hygroscopic, Light Sensitive |
Safety information for Ginsenoside Rk2
Computed Descriptors for Ginsenoside Rk2
New Products
Dibenzoyl-L-tartaric acid Anhydrous (Resolution Reagent) Cis-Tosylate Dibenzo[b,f][1,4]thiazepin-11(10H)-one 1,2,3,9-Tetrahydro-9-Methyl-4H-Carbazole-4-One 1-(4-methoxyphenyl)-4-(4-Nitrophenyl)Piperazine (IT-1) BOC Piperazine 1-Benzhydrylazetane-3-carbonitrile 8-oxa-1,3-diazaspiro[4.5]decane-2,4-dione (±)-amino(2-fluorophenyl)acetic acid 2-(2-Chlorophenyl)glycine AMINO-(3-CHLORO-PHENYL)-ACETIC ACID 2'-Fluoroacetophenone METHANOL-D1(OD) TERTIARY BUTANOL-D9 N-ETHYL-D5-AMINE HYDROCHLORIDE BENZOIC ACID-D CHLOROFORM-D TOLUENE-D3 Trans,trans muconic acid HC Blue-16 4-Amino-2-chloro-6,7-dimethoxyquinazoline Ethyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate 2,3-Dimethoxypyridine 1-(3-Chlorophenyl)piperazine hydrochlorideRelated products of tetrahydrofuran
You may like
-
Product IntroductionView Details -
Product InrtroductionView Details -
DGO24View Details -
DGO25View Details -
DGO29View Details -
DGO32View Details -
DGO36View Details -
DGO37View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.